Pimecrolimus for psoriasis
| Autor: | Helen S. Young, Jean Ayer |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Calcineurin Inhibitors MEDLINE Administration Oral Intertriginous Administration Cutaneous Tacrolimus Pimecrolimus Psoriasis medicine Animals Humans Pharmacology (medical) In patient Adverse effect Pharmacology business.industry General Medicine medicine.disease Dermatology Calcineurin Dermatologic Agents business medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 14:767-774 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.2013.775247 |
| Popis: | Introduction: Pimecrolimus is a calcineurin inhibitor which has a role in the treatment of psoriasis. However, it remains an off-license treatment, despite its potential use in patients with treatment-resistant psoriasis or in those who have had multiple adverse effects to other therapies. Areas covered: This review covers the efficacy and role of both topical and oral Pimecrolimus in the management of psoriasis and compares them to other available treatments. The paper provides a comprehensive review of the literature on topical and oral Pimecrolimus and its utility in the treatment of patients with psoriasis following literature searches via PubMed and Embase. Expert opinion: Topical Pimecrolimus is an effective, off-license treatment option particularly for facial and intertriginous psoriasis. Oral Pimecrolimus shows great promise as an alternative systemic treatment option, but Phase III trials are required before further recommendations can be made. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|